These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33887727)

  • 21. The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.
    Gralla J; Wiseman AC
    Transplantation; 2010 Sep; 90(6):639-44. PubMed ID: 20595929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive T-cell antibody induction for heart transplant recipients.
    Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis.
    Schwarz C; Böhmig G; Steininger R; Unger L; Kristo I; Kozakowski N; Berlakovich GA; Soliman T; Mühlbacher F
    Transplant Proc; 2015 Oct; 47(8):2446-9. PubMed ID: 26518948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
    Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
    Ulsh PJ; Yang HC; Holman MJ; Ahsan N
    J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of Induction Therapy Using Basiliximab With Delayed Tacrolimus Administration in Heart Transplant Recipients　- Comparison With Standard Tacrolimus-Based Triple Immunosuppression.
    Watanabe T; Yanase M; Seguchi O; Fujita T; Hamasaki T; Nakajima S; Kuroda K; Kumai Y; Toda K; Iwasaki K; Kimura Y; Mochizuki H; Anegawa E; Sujino Y; Yagi N; Yoshitake K; Wada K; Matsuda S; Takenaka H; Ikura M; Nakagita K; Yajima S; Matsumoto Y; Tadokoro N; Kakuta T; Fukushima S; Ishibashi-Ueda H; Kobayashi J; Fukushima N
    Circ J; 2020 Nov; 84(12):2212-2223. PubMed ID: 33148937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction therapy: clinical and quality of life outcomes in aged renal transplant recipients.
    Palanisamy AP; Al Manasra AR; Pilch NA; Dowden JE; Nadig SN; McGillicuddy JW; Baliga PK; Chavin KD; Taber DJ
    Clin Transplant; 2015 Mar; 29(3):222-6. PubMed ID: 25557762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction regimen and survival in simultaneous heart-kidney transplant recipients.
    Ariyamuthu VK; Amin AA; Drazner MH; Araj F; Mammen PPA; Ayvaci M; Mete M; Ozay F; Ghanta M; Mohan S; Mohan P; Tanriover B
    J Heart Lung Transplant; 2018 May; 37(5):587-595. PubMed ID: 29198930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group.
    Miller J; Mendez R; Pirsch JD; Jensik SC
    Transplantation; 2000 Mar; 69(5):875-80. PubMed ID: 10755543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.
    Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Superior Patient and Graft Survival in Adult Liver Transplant with Rabbit Antithymocyte Globulin Induction: Experience with 595 Patients.
    Montenovo MI; Jalikis FG; Li M; Yeh M; Dick A; Hansen R; Reyes JD
    Exp Clin Transplant; 2017 Aug; 15(4):425-431. PubMed ID: 27309029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of induction modality on the outcome of deceased donor kidney transplant recipients discharged on steroid-free maintenance immunosuppression.
    Sureshkumar KK; Thai NL; Hussain SM; Ko TY; Marcus RJ
    Transplantation; 2012 Apr; 93(8):799-805. PubMed ID: 22290269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
    Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage.
    Liu CL; Fan ST; Lo CM; Chan SC; Ng IO; Lai CL; Wong J
    Liver Transpl; 2004 Jun; 10(6):728-33. PubMed ID: 15162466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mycophenolate mofetil without antibody induction in cadaver vs. living donor pediatric renal transplantation.
    Ojogho O; Sahney S; Cutler D; Baron PW; Abdelhalim FM; Hasan SM; Concepcion W
    Pediatr Transplant; 2003 Apr; 7(2):137-41. PubMed ID: 12654055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients.
    Penninga L; Penninga EI; Møller CH; Iversen M; Steinbrüchel DA; Gluud C
    Cochrane Database Syst Rev; 2013 May; (5):CD008817. PubMed ID: 23728681
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction Therapy With ATG Compared With Anti-IL2 Basiliximab in Low-Immunologic Risk Kidney Transplant Recipients.
    Dedinská I; Graňák K; Vnučák M; Skálová P; Laca Ĺ; Krivuš J; Galajda P; Mokáň M
    Transplant Proc; 2019 Dec; 51(10):3259-3264. PubMed ID: 31732198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens.
    Krämer BK; Krüger B; Mack M; Obed A; Banas B; Paczek L; Schlitt HJ
    Transplant Proc; 2005 May; 37(4):1789-91. PubMed ID: 15919467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.